| 查看: 734 | 回复: 0 | |||||
wachina至尊木虫 (知名作家)
|
[交流]
曲美替尼获得英国2013年药物发现奖
|
|
First-of-its-kind treatment for skin cancer offers hope for patients and their families The British Pharmacological Society proudly announces that its Drug Discovery of the Year award has been won by the team at GlaxoSmithKline (GSK) responsible for the development of trametinib – a new treatment for malignant melanoma (a type of skin cancer). “The Drug Discovery of the Year award celebrates the crucial role of pharmacologists in the development of new medicines,” explains Professor Routledge, President of the British Pharmacological Society. “The GSK team behind trametinib has been singled out for recognition because of the way in which they created a ‘first-in-class’ medicine for a devastating disease by building upon successful early research in animals.” There are about 12,000 new cases of malignant melanoma diagnosed every year in the UK, with a significantly greater proportion proving fatal than other types of skin cancer (about 2,000 deaths each year)[1]. Malignant melanoma is caused by exposure to UV light, which may be naturally from sunlight, or artificially through tanning beds and certain types of work. It is the third most common cancer in the 15 to 39 year age group [2]. Dr Ann Hayes, Fellow of the British Pharmacological Society and chair of the judging panel, confirms: “This year’s nominees for Drug Discovery of the Year all demonstrated excellence in pharmacology and were difficult to separate. Trametinib was distinguished by its novel translational pharmacology, but undoubtedly the judges were also impressed by the GSK team’s ambition to address the impact of malignant melanoma on the lives of so many patients and their families.” The Society will present the award at its annual meeting Pharmacology 2013, which is being held this week in London. The winning team was selected by a judging panel of experts in industrial pharmacology. Drs Aidan Gilmartin and Kiran Patel will collect the award on behalf of the scientists who contributed towards the development of trametinib. 曲美替尼（trametinib）是GlaxoSmithKline开发的MEK抑制剂，制剂采用DMSO溶剂合物。该药与Tafinlar同时获得FDA批准，用于治疗不可切除或已经转移的BRAF V600E或V600K基因突变型黑色素瘤，但不适用于之前已经接受BRAF抑制剂治疗的患者。在一项国际多中心、随机、开放标签、对照试验中，322例BRAF V600E或V600K阳性黑色素瘤患者按2:1分成曲美替尼治疗组和常规化疗组。结果显示，曲美替尼治疗组中位无进展生存期为4.8个月，常规化疗组中位无进展生存期为1.5个月。 |
回复此楼» 收录本帖的淘帖专辑推荐
 颛顼药学 | 新药仿药 |
» 猜你喜欢
多聚组氨酸，大分子量
已经有647人回复
-
胰岛素的实验室表达
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有120人回复
-
胰岛素的实验室表达
已经有0人回复
-
胰岛素的实验室表达
已经有0人回复
-
胰岛素的实验室表达
已经有1人回复
-
胰岛素的实验室表达
已经有0人回复
-
胰岛素的实验室表达
已经有0人回复
-
求助电子版：晶型药物研发理论与应用
已经有0人回复
-
北京大学药学院诚招药物化学/有机化学方向博士后
已经有5人回复
